Option chain shows key data for Histogen Inc COM NEW's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Histogen Inc COM NEW.

Histogen Inc COM NEW (OTC:HSTO) Stock, Option Chain

Histogen

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AGIL

AIRI

ALLG

ALXO

AMPX

ARAY

ATEN

BCLI

BENF

BIAF

BROG

CALM

CAMP

DXYN

FEMY

GLBS

HELE

HSTO

IGMS

LIFW

LPTH

LVOX

MKUL

OCEA

PFIE

PXLW

STRR

VINO

VVOS

Gainers


	Gaucho Group Holdings, Inc.  (NASDAQ: VINO) jumped 95.2% to $3.7280. Gaucho Group is planning to list two of its retail properties in Argentina, in San Rafael and Cordoba, for sale, priced at $2 million and $0.7 million respectively.


Why Cal-Maine Foods Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

AGRI

ASST

ATRA

AXLA

AZUL

BGNE

BJDX

BRDS

CATC

CLDI

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

CSPI

CZOO

DTOC

EBET

EHTH

ELUT

EVAX

FRTX

GRRR

HAIN

IBRX

ICCM

NMRA

NVOS

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

RNAZ

SEEL

SPRY

SWIN

Gainers

MSP Recovery, Inc.  (NASDAQ: LIFW) shares jumped 104.5% to $0.1916.

Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Pre-Market Outlook

AVGR

CYBN

EXAI

MBOT

RVNC

RVSN

Gainers

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 70.2% to $0.8937 in pre-market trading after falling 10% on Tuesday.

Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket

Histogen Inc COM NEW

Histogen Inc

GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) will release its fourth-quarter financial results before the <a href="https://www.benzinga.com/quote/GE/earnings">opening bell on Thursday, Jan. 23</a>.
Analysts expect the Ohio-based company to report quarterly earnings at $1.04 per share, up from $1.03 per share in the year-ago period. GE Aerospace projects quarterly revenue of $9.47 billion, compared to $19.42 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 2, Deutsche Bank analyst Scott Deuschle maintained GE Aero with a Buy rating and lowered the price target from $235 to $228.
With the recent buzz around GE Aerospace, some investors may be eyeing potential gains from the company's dividends. As of now, GE Aerospace offers an annual dividend yield of 0.60%, which is a quarterly dividend amount of 28 cents per share ($1.12 a year).
To figure out how to earn $500 monthly from GE Aerospace, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by GE Aerospace's $1.12 dividend: $6,000 / $1.12 = 3,000 shares.
So, an investor would need to own approximately $1,004,438 worth of GE Aerospace, or 5,357 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.12 = 1,071 shares, or $200,813 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
GE Price Action: Shares of GE Aerospace gained by 2.5% to close at $187.50 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>

Long Ideas

How To Earn $500 A Month From GE Aerospace Stock Ahead Of Q4 Earnings

WIIM

USEG

U.S. Energy Corp shares are trading higher. The company announced a public offering of 4,236,000 shares.

Barclays analyst Kannan Venkateshwar downgrades BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) from Equal-Weight to Underweight and lowers the price target from C$41 to C$30.

Downgrades

Price Target

Analyst Ratings

TSX:BCE

Barclays Downgrades BCE to Underweight, Lowers Price Target to C$30

LSTA

Lisata Therapeutics shares are trading lower after the company announced preliminary cohort data from its Phase 2 Ascend trial.

HPAI

Helport AI Partners With LendSure To Boost Loan Officer Productivity, Reduce Overhead Costs, And Lower Mortgage Expenses For Borrowers; Aims For Industry-Wide Transformation Through AI Integration

HEPA

Hepion Pharmaceuticals shares are trading lower after the company announced a $9 million public offering.

BLBX

Blackboxstocks shares are trading higher after the company announced a $250K securities purchase agreement and is anticipating a potential merger.

Offerings

U.S. Energy Corp. Prices 4,236,000 Share Offering At $2.65/Share

Goldman Sachs CEO Solomon Says Rebalancing Of Certain Trade Agreements Over Time Can Be Constructive For U.S. Growth; I Think It's Hard To Dispute The Fact That Equity Multiples Are High

Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS
The early-onset broad-spectrum antiviral effect of Ampligen has been observed to stimulate strong innate immune response, offering potential therapeutic benefits for people with ME/CFS or Post-COVID chronic fatigue
OCALA, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Lp7r-Zko8_STxa2-SCTwWJh1YHEsWboXq5jsxeXHg-SqFEWiqVGMujh5tpqwQxZY5yu2XZuEKP-kqNipNfkoTz27dgqboQ8x6ThGGR7FHqU=">AIM ImmunoTech Inc.</a> (NYSE:<a href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>)&nbsp;("AIM" or the "Company") today offered commentary on a new article in the Journal of General Internal Medicine linking COVID-19 to increased risk of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome ("ME/CFS").
The article, titled "<a href="https://www.globenewswire.com/Tracker?data=Fpq1FisR8Jo1G0UQe1w_Xfyq974COCvW4D_zDbhx6_5A0ny4E4Th5BAnjftaot2-CBsrvkrvPy4vLK9ZH3_XPf6BEtDKxILgAsWUrhbxQtb9G1eL_d0RHXTAtQyiV1dDgtvGWyL_CXYP8dEKM0sl_e5o6kWll7Ml4HPjKmEAZbaCJFKGMw0km6H3jqqnBplMJoqzXHwWq6c0FZBZ48Kk9SNpfqFRHl4ud2cVHkg-JSiJXXFaA4j39hkqvOp3hWvEPVi255ewcc5zYELBzc3yQw==">Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study</a>," found that among study participants infected with SARS-CoV-2, the incidence of ME/CFS was 15 times higher than pre-pandemic rates. The article's lead author, Suzanne D. Vernon, PhD, emphasized the following highlights in an <a href="https://www.globenewswire.com/Tracker?data=IFH4V9qJpmVon0e6WwLx9F-9dJ-PXSwcqmf6AWGKFGpioE4g2C0XT-vTSog6ur1kSKv3Tqel3TlMk2tZv_ZxO8FrpaAyqaJe6oAT9qQmwriMCO59gtO7iuWk983XNcr_9yKUh6iDzSoInm9YYBi9MQ==">accompanying analysis</a> posted to the Bateman Horne center website:
<ul>
<li>Of the 4,515 participants who enrolled within 30 days of contracting COVID-19, 73 developed ME/CFS at least six months post-infection.</li>
<li>In total, 531 participants met ME/CFS criteria, translating to a prevalence of 4.5% among those infected—nearly eight times higher than uninfected participants.</li>
<li>This prevalence is five times higher than pre-pandemic estimates and underscores the severe and lasting impact of COVID-19 on public health.
<ul>
<li>90% of these post-COVID-19 ME/CFS cases clustered with the most symptomatic and severe cases of Long COVID, highlighting the overlap between these two conditions.</li>
</ul>
</li>
</ul>

Biotech

General

AIM ImmunoTech Announces Commentary On Study Linking COVID-19 To Increased ME/CFS Risk; Incidence 15 Times Higher Than Pre-Pandemic Rates; Ampligen Shows Strong Antiviral Effect Beneficial For ME/CFS And Post-COVID Fatigue; 531 Of 4,515 Participants Affected

Carnival Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) is charting a multi-year growth path and JPMorgan analyst Matthew R. Boss sees <a href="https://www.benzinga.com/topic/cruise-lines">the cruise giant</a> setting sail for stronger returns in 2025 and beyond.
After an exclusive shipboard chat with Carnival's top brass, Boss highlights key catalysts that could drive the next leg of the stock's performance.
<h2 class="wp-block-heading">Growth Beyond The Horizon</h2>
CEO Josh Weinstein sees Carnival's diversified portfolio of eight brands as a key advantage over smaller peers, with Carnival and AIDA already surpassing 2019 performance metrics. The real opportunity? The remaining six brands, many still trailing pre-pandemic levels, are now under Weinstein's direct oversight after organizational shifts. With a focus on marketing and execution, management is counting on a strong 2025-2026 ramp-up.
While the industry worries about overcapacity, Carnival is taking a disciplined approach, adding just 0-1% annual capacity growth, well below the pre-pandemic 3%. With only 2-3% of global hotel stays coming from cruises, the U.S. and Canada remain a largely untapped market.
Read Also: <a href="https://www.benzinga.com/24/12/42657003/analysts-see-smooth-sailing-for-carnival-as-q4-results-beat-expectations">After Carnival&#8217;s Q4 Performance, Analysts See Smooth Sailing</a>
<h2 class="wp-block-heading">AI, Yield Management &amp; A &#8216;Magic Kingdom&#8217; At Sea</h2>
Carnival's revenue play isn't just about record bookings, it's about smart pricing. Enter &#8216;YODA&#8217; the company's AI-driven yield management system, designed to maximize revenue. Early results look promising, with new-to-cruise guests up 13% year-over-year and repeat bookings climbing 10%.
Meanwhile, Carnival is expanding its strategic destination assets, with the upcoming Celebration Key, set to open in mid-2025. By 2030, the company aims to handle 11 million guests annually—nearly double the 6.5 million expected in 2024. Daily capacity across its destinations will rise to 95,000, rivaling the foot traffic of Disney's Magic Kingdom.
<h2 class="wp-block-heading">Balance Sheet Detox</h2>
Debt reduction remains a priority, with Carnival slashing $7.3 billion in debt since early 2023. Interest expenses are already down 15% year-over-year, with CFO David Bernstein targeting a return to sub-3.5x leverage by FY26, a significant improvement from 6.7x in FY23.
<h2 class="wp-block-heading">Industry Implications: FX, Fuel &amp; Competitive Positioning</h2>
While Carnival is executing its multi-year plan, foreign exchange and fuel volatility remain headwinds for the broader industry. JPMorgan has adjusted (lowered) its earnings models for key competitors Royal Caribbean Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) and Norwegian Cruise Line Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) based on recent currency shifts and fuel cost increases. 
<h2 class="wp-block-heading">Investor Takeaway</h2>
Carnival is more than 80% of the way to its <a href="https://www.prnewswire.com/news-releases/carnival-corporation--plc-reports-second-quarter-2023-earnings-and-sets-sights-on-2026-sea-change-program-301862616.html">SEA Change</a> transformation targets, with long-term return on invested capital (ROIC) expected to land "at least in the teens" by 2026. With disciplined growth, AI-driven revenue strategies, and a revamped balance sheet, Carnival looks well-positioned to navigate the next phase of industry expansion. 
Investors betting on the cruise rebound might find Carnival's multi-year story compelling, especially as it leans into pricing power, brand execution and strategic destinations.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42490038/norwegian-cruise-line-benefits-from-re-energized-consumer-spending-and-cost-savings-program-analyst-says">Norwegian Cruise Line Benefits From Re-energized Consumer Spending And Cost Savings Program, Analyst Says</a></li>
</ul>

Analyst Color

Entertainment

Travel

NCLH

Carnival's Transformation: AI-Driven Yields And A Balance Sheet Reset

Comerica Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) shares are trading lower in premarket Wednesday after the <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000028412/000002841225000005/cma-20250122.htm" rel="noreferrer noopener">fourth-quarter FY24 earnings result</a>.
The financial services company reported a fourth-quarter revenue increase of 5.5% to $825 million, missing the analyst consensus estimate of $837.98 million.
Net interest income increased $41 million to $575 million quarter-on-quarter, reflecting a strategic growth in core interest-bearing deposits and relationship-focused pricing.
Adjusted EPS of $1.20 also <a href="https://www.benzinga.com/earnings">missed the consensus estimate of $1.28.</a>
Average loans in the fourth quarter amounted to $50.62 billion and the return on average assets stood at 0.85%. Efficiency ratio for the quarter was 69.51.
Nonperforming assets increased $58 million to $308 million, or 0.61% of total loans and foreclosed property, compared to 0.50% in the third quarter of 2024.
The company held $850 in cash and equivalents as of December 31, 2024.
Curtis C. Farmer, Comerica Chairman and Chief Executive Officer, stated, &#8220;As expected, loans were pressured by paydowns in Commercial Real Estate, but we saw promising signals across other businesses that support our outlook for growth in 2025. Although some uncertainty remains, we believe customer sentiment is generally more optimistic about the future of the economy and plans for increased investment in their businesses.&#8221;
Outlook: Comerica <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000028412/000002841225000005/cma-20250122.htm" rel="noreferrer noopener">sees </a>FY25 net interest income growth of 6% &#8211; 7%, including the impact of BSBY cessation.
For the first quarter, the company expects net interest income to decline 1% &#8211; 2% sequentially, including the impact of BSBY cessation.
The company targets share repurchases at approximately <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$50 million in the first quarter of 2025</a>.
Price Action: CMA shares traded lower by 1.78% at $65.20 in premarket at the last check Wednesday.
Image: Shutterstock/ fizkes.

Equities

Guidance

Comerica Q4 Earnings: Revenue And EPS Fall Short Amid Loan Pressures, Eyes 2025 Growth

Real Estate

PGRE

Paramount Group Sells 45% Interest In 900 Third Avenue Office Building At Gross Asset Valuation Of $210M

Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) reported its Q4 earnings results on Wednesday, January 22, 2025 at 08:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Amphenol beat estimated earnings by 10.0%, reporting an EPS of $0.55 versus an estimate of $0.5.
Revenue was up $990.00 million from the same period last year.
<h3>Earnings History Overview</h3>
The company beat on EPS by $0.05 in the previous quarter, leading to a 2.0% increase share price change the next day.
Here's a look at Amphenol's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.45</td>
<td>0.41</td>
<td>0.37</td>
<td>0.39</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.50</td>
<td>0.44</td>
<td>0.40</td>
<td>0.41</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.80B</td>
<td>3.39B</td>
<td>3.10B</td>
<td>3.15B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>4.04B</td>
<td>3.61B</td>
<td>3.26B</td>
<td>3.33B</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Amphenol management provided guidance for Q1 2025, expecting earnings between $0.49 and $0.51 per share.
To track all earnings releases for Amphenol <a href="https://www.benzinga.com/quote/APH/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Amphenol Earnings Review: Q4 Summary

Houston American Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) (the "Company") today announced that it has entered into a definitive agreement with several investors for the purchase and sale of an aggregate of 2,600,000 shares of the Company's common stock, par value $0.001 per share (the "Common Stock") at a purchase price of $1.70 per share in a registered direct offering.
The aggregate gross proceeds to the Company of this offering are expected to be approximately $4,420,000. The transaction is expected to close on or about January 23, 2025, subject to the satisfaction of customary closing conditions.
Univest Securities, LLC is acting as the sole placement agent.

HUSA

Houston American Energy Corp. Announces $4.42M Registered Direct Offering Of 2.6M Shares Of Common Stock At A Price Of $1.70/Share

LOBO

Lobo EV Technologies Entered Into a Letter Of Intent With Roundtree Lab To Manufacture Smart Electric Medical Transport Beds

Decent Holding Inc. (the "Company"), an established wastewater treatment services provider in China, today announced the pricing of its initial public offering (the "Offering") of 1,250,000 ordinary shares (the "Ordinary Shares") at a public offering price of $4.00 per share. The Company expects to receive aggregate gross proceeds of $5 million, before deducting underwriting discounts and other offering expenses. The Ordinary Shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on January 22, 2025, under the ticker symbol "DXST". The Offering is expected to close on January 23, 2025, subject to the satisfaction of customary closing conditions. In addition, the Company has granted the underwriters an option (the "Over-Allotment Option"), within 45 days from the closing date of the Offering, to purchase up to an additional 187,500 Ordinary Shares at the public offering price, less underwriting discounts, to cover the Over-Allotment Option, if any.
The net proceeds from the Offering will be used for (i) business expansion; (ii) research and development; (iii) promoting the river water quality management service and expanding the treatment scope of river water; (iv) development and upgrade of wastewater treatment technology; and (v) recruiting talents in research and development and management.

IPOs

DXST

Decent Holding Inc. Announces Pricing Of $5M Initial Public Offering Of 1.25M Shares At A Price Of $4/Share

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Technologies Says Its ART100 Systems Have Been Delivered To Glo-Med Networks And Are Preparing For Deployment At A US Hospital

Ormat Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORA#NYSE">ORA</a>), a leading geothermal and renewable energy company, today announced the signing of a 10-year Power Purchase Agreement (PPA) with Calpine Energy Solutions, one of North America's largest energy suppliers. Under this agreement, Calpine Energy Solutions will purchase up to 15 megawatts (MW) of clean, renewable energy from the Mammoth 2 geothermal power plant located near Mammoth Lakes, California, to support demand within its retail portfolio.
Energy deliveries under the PPA are set to begin in the first quarter of 2027 and will replace the existing PPA with the Southern California Edison Company (SCE). Notably, the new PPA, which includes an increase in production capacity and a higher price point, highlights the tight supply-demand balance of carbon-differentiated electricity in California, driven by state Renewable Portfolio Standards (RPS) compliance needs and voluntary corporate demand.

Ormat Technologies Announces 10-Year PPA With Calpine Energy Solutions For Up To 15MW From Mammoth 2 Geothermal Plant Starting Q1 2027; Replacing Southern California Edison Deal, Reflecting California's Carbon-Differentiated Electricity Demand

The Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) reported upbeat fourth-quarter results on Tuesday.
Revenue rose 20% year over year to $5.33 billion, beating the consensus of $5.19 billion.
Net interest revenue rose 19% Y/Y to $2.531 billion in the fourth quarter. Clients' daily average trades totaled 6.312 million, up 22% Y/Y.
Adjusted net income rose 44% Y/Y to $1.97 billion. Adjusted EPS increased 49% to $1.01, beating the consensus of $0.91.
Total client assets rose 19% Y/Y to $10.10trillion. The company's active brokerage accounts reached 36.5 million in the quarter.
Mike Verdeschi, CFO, said, "Client transactional sweep cash grew by $35 billion versus 3Q24, including a $25 billion increase in December due to typical year-end seasonality. This build helped us further reduce Bank Supplemental Funding by $14.9 billion to $49.9 billion – down ~50% from peak levels."
Charles Schwab shares gained 5.9% to close at $80.93 on Tuesday.
These analysts made changes to their price targets on Charles Schwab following earnings announcement.
<ul>
<li>Wells Fargo analyst Michael Brown upgraded Charles Schwab from Equal-Weight to Overweight and raised the price target from $89 to $93.</li>
<li>Barclays analyst Benjamin Budish maintained the stock with an Overweight and raised the price target from $95 to $96.</li>
<li>Citigroup analyst Christopher Allen maintained Charles Schwab with a Neutral and raised the price target from $80 to $85.</li>
<li>Deutsche Bank analyst Brian Bedell maintained Charles Schwab with a Buy and boosted the price target from $98 to $105.</li>
</ul>
Considering buying SCHW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="492" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22083203/image-154-1024x492.png" alt="" class="wp-image-744746" style="width:530px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22083203/image-154-1024x492.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22083203/image-154-300x144.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22083203/image-154-768x369.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22083203/image-154.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/43123084/top-3-health-care-stocks-that-could-blast-off-this-quarter">Top 3 Health Care Stocks That Could Blast Off This Quarter</a></li>
</ul>

SCHW

Charles Schwab Analysts Increase Their Forecasts After Upbeat Results

HC Wainwright & Co.

Comments

Histogen Inc COM NEW

Histogen Inc COM NEW (HSTO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga